Treating obesity in patients with cardiovascular disease: the pharmacotherapeutic options
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Treating obesity in patients with cardiovascular disease: the pharmacotherapeutic options
Authors
Keywords
-
Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume -, Issue -, Pages 1-9
Publisher
Informa UK Limited
Online
2019-01-09
DOI
10.1080/14656566.2018.1561867
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes
- (2018) Brendan M. Everett et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
- (2018) Patrick M O'Neil et al. LANCET
- Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients
- (2018) Erin A. Bohula et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes
- (2017) Melanie Davies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Health Effects of Overweight and Obesity in 195 Countries over 25 Years
- (2017) NEW ENGLAND JOURNAL OF MEDICINE
- Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
- (2017) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of orlistat on plasma lipids and body weight: A systematic review and meta-analysis of 33 randomized controlled trials
- (2017) Amirhossein Sahebkar et al. PHARMACOLOGICAL RESEARCH
- Anti-Inflammatory Effects of Metformin Irrespective of Diabetes StatusNovelty and Significance
- (2016) Amy R. Cameron et al. CIRCULATION RESEARCH
- SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study
- (2016) Muhammad Abdul-Ghani et al. DIABETES CARE
- Weight management in obesity - past and present
- (2016) D. Haslam INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors
- (2016) Steven E. Nissen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Trends in Obesity Among Adults in the United States, 2005 to 2014
- (2016) Katherine M. Flegal et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Persistent metabolic adaptation 6 years after “The Biggest Loser” competition
- (2016) Erin Fothergill et al. Obesity
- Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial
- (2016) Lancet Diabetes & Endocrinology
- Heart Disease and Stroke Statistics—2016 Update
- (2015) Dariush Mozaffarian et al. CIRCULATION
- Energy Balance After Sodium–Glucose Cotransporter 2 Inhibition
- (2015) Giulia Ferrannini et al. DIABETES CARE
- Liraglutide: A Review of Its Use in the Management of Obesity
- (2015) Lesley J. Scott DRUGS
- Naltrexone ER/Bupropion ER: A Review in Obesity Management
- (2015) Sarah L. Greig et al. DRUGS
- Combination phentermine and topiramate extended release in the management of obesity
- (2015) Nasreen Alfaris et al. EXPERT OPINION ON PHARMACOTHERAPY
- Lorcaserin Hcl for the treatment of obesity
- (2015) Alpana P Shukla et al. EXPERT OPINION ON PHARMACOTHERAPY
- Physiological adaptations to weight loss and factors favouring weight regain
- (2015) F L Greenway INTERNATIONAL JOURNAL OF OBESITY
- Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
- (2015) Caroline M. Apovian et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
- (2015) Xavier Pi-Sunyer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology
- (2014) Sanjay Kalra Diabetes Therapy
- Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes
- (2013) Despoina Vasilakou et al. ANNALS OF INTERNAL MEDICINE
- 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
- (2013) Michael D. Jensen et al. CIRCULATION
- Effects of Naltrexone Sustained- Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes
- (2013) P. Hollander et al. DIABETES CARE
- Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes
- (2013) NEW ENGLAND JOURNAL OF MEDICINE
- A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II)
- (2013) Caroline M. Apovian et al. Obesity
- Use of Prescription Antiobesity Drugs in the United States
- (2013) Christian Hampp et al. PHARMACOTHERAPY
- Prevalence of Obesity and Trends in the Distribution of Body Mass Index Among US Adults, 1999-2010
- (2012) Katherine M. Flegal et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial
- (2011) Kishore M Gadde et al. LANCET
- Long-Term Persistence of Hormonal Adaptations to Weight Loss
- (2011) Priya Sumithran et al. NEW ENGLAND JOURNAL OF MEDICINE
- Blood Pressure and Heart Rate Effects, Weight Loss and Maintenance During Long-Term Phentermine Pharmacotherapy for Obesity
- (2011) Ed J. Hendricks et al. Obesity
- Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP)
- (2011) David B. Allison et al. Obesity
- Randomized controlled trial to investigate the effects of a newly developed formulation of phentermine diffuse-controlled release for obesity
- (2010) J. G. Kang et al. DIABETES OBESITY & METABOLISM
- Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation
- (2010) Lotte Bjerre Knudsen et al. ENDOCRINOLOGY
- Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
- (2010) Frank L Greenway et al. LANCET
- Multicenter, Placebo-Controlled Trial of Lorcaserin for Weight Management
- (2010) Steven R. Smith et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects
- (2010) W. Philip T. James et al. NEW ENGLAND JOURNAL OF MEDICINE
- Weight Loss With Naltrexone SR/Bupropion SR Combination Therapy as an Adjunct to Behavior Modification: The COR-BMOD Trial
- (2010) Thomas A. Wadden et al. Obesity
- Prognostic importance of weight loss in patients with coronary heart disease regardless of initial body mass index
- (2008) Justo Sierra-Johnson et al. EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION
- Sibutramine-associated adverse effects: a practical guide for its safe use
- (2007) M. Florentin et al. Obesity Reviews
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started